Should avoid sexual contact while visible lesions are present because of the risk of infecting intimate partners.
Should be cautious not to exceed the prescribed dosage.
The results of a wide range of mutagenicity tests in vitro and in vivo indicate that acyclovir does not pose a genetic risk to a man.
Acyclovir was not found to be carcinogenic in long term studies in the rat and the mouse. Largely reversible adverse effects on the spermatogenesis in association with overall toxicity in rats and dogs have been reported only at doses of acyclovir greatly in excess of those employed therapeutically.
Acyclovir tablet have been shown to have no definite effect upon sperm count, morphology or motility in man.
Use in pregnancy: Limit data are available on the use of acyclovir in pregnancy.
Caution should therefore be exercised by balancing the potential benefits of treatment against any possible hazard.
Use in lactation: Limited data indicate that acyclovir is distributed into milk following systemic administration. Caution therefore advised if ZEVIN is to be administered to a nursing woman.